Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Anika Therapeutics's share price for the quarter that ended in Mar. 2026 was €12.4. Anika Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 13.36 Mil. Therefore, Anika Therapeutics's market cap for the quarter that ended in Mar. 2026 was €165.63 Mil.
Anika Therapeutics's quarterly market cap
declined
from Sep. 2025 (€111.04 Mil) to Dec. 2025 (€110.42 Mil) but then
increased
from Dec. 2025 (€110.42 Mil) to Mar. 2026 (€165.63 Mil).
Anika Therapeutics's annual market cap
declined
from Dec. 2023 (€299.06 Mil) to Dec. 2024 (€222.01 Mil) and
declined
from Dec. 2024 (€222.01 Mil) to Dec. 2025 (€110.42 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Anika Therapeutics's Enterprise Value for Today is €173.55 Mil.
Anika Therapeutics (STU:AKP) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Anika Therapeutics Market Cap Related Terms
Anika Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Anika Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:AKP vs LFCR, DERM, ASRT: Market Cap Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Anika Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anika Therapeutics Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anika Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Anika Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Anika Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anika Therapeutics (STU:AKP) has a Market Cap of €186.97 Mil as of Jul. 07, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Anika Therapeutics and its competitors. According to the industry distribution chart, Anika Therapeutics ranks #520 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 50.8%.
Is Anika Therapeutics' Market Cap too high?
Anika Therapeutics' current Market Cap is €186.97 Mil. Based on the distribution chart, Anika Therapeutics ranks #520 out of 1024 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Anika Therapeutics has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anika Therapeutics' Market Cap compare to LFCR and DERM?
According to the Drug Manufacturers industry distribution chart, Anika Therapeutics ranks #520 out of 1024 companies for Market Cap. This places Anika Therapeutics in the lower half of its industry. The industry median Market Cap is 214.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 214.89, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Anika Therapeutics and its competitors. For the Drug Manufacturers industry, the median Market Cap is 214.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anika Therapeutics's current Market Cap is €186.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anika Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Anika Therapeutics (STU:AKP) is currently considered Modestly Undervalued. The stock's GF Value™ is €17.65, compared to a current price of €13.80 — trading 21.8% below its estimated fair value. The current Market Cap is €186.97 Mil. Anika Therapeutics' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Anika Therapeutics (STU:AKP), the current Market Cap is €186.97 Mil as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anika Therapeutics (STU:AKP) Overvalued in 2026?
Based on GuruFocus' analysis, Anika Therapeutics stock appears to be undervalued.
The current stock price of €13.80 is trading 21.8% below its estimated GF Value™ of €17.65.
GuruFocus considers Anika Therapeutics to be Modestly Undervalued.
Key valuation signals for STU:AKP:
Market Cap: €186.97 Mil
GF Value™: €17.65 vs. price of €13.80 (21.8% below fair value)
No single metric tells the full story. See the STU:AKP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
66GF Score
Get the complete analysis for STU:AKP
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AKP has been successfully added to your 
